Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
dc.contributor.authorTRIN, Kilian
dc.contributor.authorDALLEAU, Cynthia
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMATHOULIN PELISSIER, Simone
IDREF: 071358587
dc.contributor.authorLE TOURNEAU, Christophe
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorDINART, Derek
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.date.accessioned2025-04-18T07:40:59Z
dc.date.available2025-04-18T07:40:59Z
dc.date.issued2025-03-29
dc.identifier.issn1534-6269en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206265
dc.description.abstractEnPURPOSE OF REVIEW: The growth modulation index (GMI) is defined as the ratio between the time to progression of a new line of treatment and the previous line. This ratio can be used to determine whether the new line of treatment brings a clinical benefit. It has been proposed as an outcome in trials evaluating non-cytotoxic drugs. Its interest lies in the intra-patient comparison. The terminology employed to refer to the GMI, as well as its definitions, are highly variable in the literature. Some uses of the GMI are arbitrary and not based on any scientific rationale. Our aim is to describe how the GMI is reported in the scientific literature. RECENT FINDINGS: We carried out a scoping review using PubMed, Scopus, Web of Science and BASE (Bielefeld Academic Search Engine). The algorithm was composed of the terms "growth modulation index", "time to progression ratio" and "progression-free survival ratio". Documents in English, with full-text available, published up to 2023, were included. Among 227 included documents, 166 of which discussed GMI specifically. On these 166 documents, 76 reported on observational studies, 62 on interventional studies and 17 on methodological or statistical developments pertaining to the GMI. All were about oncology. Our review highlights significant variability in the reporting and use of the GMI. To address this, we propose standardized reporting guidelines. Additionally, we emphasize the need for methodological and statistical developments to improve the use of the GMI and to develop novel GMI-based trial designs.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enGrowth modulation index
dc.subject.enGuidelines
dc.subject.enOncology
dc.subject.enProgression-free survival ratio
dc.subject.enScoping review
dc.subject.enTime to progression ratio
dc.title.enThe Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines
dc.title.alternativeCurr Oncol Repen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s11912-025-01667-1en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed40156702en_US
bordeaux.journalCurrent Oncology Reportsen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut National Du Canceren_US
bordeaux.identifier.funderIDFondation Bergoniéen_US
hal.identifierhal-05039118
hal.version1
hal.date.transferred2025-04-18T07:41:02Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Current%20Oncology%20Reports&rft.date=2025-03-29&rft.eissn=1534-6269&rft.issn=1534-6269&rft.au=TRIN,%20Kilian&DALLEAU,%20Cynthia&MATHOULIN%20PELISSIER,%20Simone&LE%20TOURNEAU,%20Christophe&DINART,%20Derek&rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem